Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

J. Balzarini; E. Keyaerts; L. Vijgen; H.F. Egberink; E. de Clercq; M. van Ranst; S.S. Printsevskaya; E.N. Olsufyeva; S.E. Solovieva; M.N. Preobrazhenskaya

doi:10.1016/j.antiviral.2006.03.005

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

J. Balzarini, E. Keyaerts, L. Vijgen, H.F. Egberink, E. de Clercq, M. van Ranst, S.S. Printsevskaya, E.N. Olsufyeva, S.E. Solovieva, M.N. Preobrazhenskaya

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivatives for FIPV or SARS-CoV.

Original language	English
Pages (from-to)	20-33
Number of pages	14
Journal	Antiviral Research
Volume	72
Issue number	1
DOIs	https://doi.org/10.1016/j.antiviral.2006.03.005
Publication status	Published - 2006

Keywords

Coronaviruses
FIPV
SARS
Glycopeptide antibiotics
Vancomycin
Teicoplanin
Eremomycin

Access to Document

10.1016/j.antiviral.2006.03.005

Cite this

Balzarini, J., Keyaerts, E., Vijgen, L., Egberink, H. F., de Clercq, E., van Ranst, M., Printsevskaya, S. S., Olsufyeva, E. N., Solovieva, S. E., & Preobrazhenskaya, M. N. (2006). Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Research, 72(1), 20-33. https://doi.org/10.1016/j.antiviral.2006.03.005

@article{9d3005533d3249d7908b5f1db292e12b,

title = "Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics",

abstract = "Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivatives for FIPV or SARS-CoV.",

keywords = "Coronaviruses, FIPV, SARS, Glycopeptide antibiotics, Vancomycin, Teicoplanin, Eremomycin",

author = "J. Balzarini and E. Keyaerts and L. Vijgen and H.F. Egberink and {de Clercq}, E. and {van Ranst}, M. and S.S. Printsevskaya and E.N. Olsufyeva and S.E. Solovieva and M.N. Preobrazhenskaya",

year = "2006",

doi = "10.1016/j.antiviral.2006.03.005",

language = "English",

volume = "72",

pages = "20--33",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

AU - Balzarini, J.

AU - Keyaerts, E.

AU - Vijgen, L.

AU - Egberink, H.F.

AU - de Clercq, E.

AU - van Ranst, M.

AU - Printsevskaya, S.S.

AU - Olsufyeva, E.N.

AU - Solovieva, S.E.

AU - Preobrazhenskaya, M.N.

PY - 2006

Y1 - 2006

N2 - Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivatives for FIPV or SARS-CoV.

AB - Various semisynthetic derivatives of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivatives modified with hydrophobic substituents showed selective antiviral activity. For the most active compounds, the 50% effective concentrations (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the molecules did not affect the antiviral activity of the compounds. Some compounds showed inhibitory activity against both, whereas other compounds proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivatives for FIPV or SARS-CoV.

KW - Coronaviruses

KW - FIPV

KW - SARS

KW - Glycopeptide antibiotics

KW - Vancomycin

KW - Teicoplanin

KW - Eremomycin

U2 - 10.1016/j.antiviral.2006.03.005

DO - 10.1016/j.antiviral.2006.03.005

M3 - Article

SN - 0166-3542

VL - 72

SP - 20

EP - 33

JO - Antiviral Research

JF - Antiviral Research

IS - 1

ER -

Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

Abstract

Keywords

Access to Document

Fingerprint

Cite this